Back to Search
Start Over
Boundless Bio Announces Clinical Trial Collaboration and Supply Agreement with Taiho Oncology to Evaluate LYTGOBI[R] (futibatinib) in Combination with BBI-355 in Patients with FGFR Amplified Solid Tumors
- Source :
- Business Wire. September 18, 2023
- Publication Year :
- 2023
-
Abstract
- Combination of BBI-355 and futibatinib to be evaluated in Boundless Bio's ongoing Phase 1/2 clinical trial (POTENTIATE) in patients with FGFR amplifications SAN DIEGO -- Boundless Bio, a clinical stage, [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- Business Wire
- Publication Type :
- News
- Accession number :
- edsgcl.765699031